A consultant has a patient with a rare condition, and the medicine she wants to prescribe is not authorised or marketed in her country. The hospital pharmacist has never ordered it, the procurement office has no contract for it, and nobody is sure which documents the national authority will want to see. Finding a rare disease medicine supplier Europe-wide is rarely the hard part; getting the request organised so that supply can actually happen is where most teams lose time.

Key points

  • Settle the legal route for access before you approach any supplier.
  • The physician’s request, the pharmacy’s import checks and the supplier’s documentation all need to line up.
  • Ask suppliers about storage, traceability and communication, not only availability.
  • Start early, because rare disease supply is often needed for a named individual with little room for delay.

Start with the access route, not the supplier

Before anyone sends an enquiry, the hospital needs to know how the medicine can lawfully reach this patient. The usual options are a locally authorised product, a product authorised in another EU member state, a named patient supply of an unlicensed medicine, a compassionate use or early access programme run by the marketing authorisation holder, or inclusion in a clinical trial. Each has different paperwork and a different owner.

Directive 2001/83/EC lets member states make their own provision for medicines supplied to meet the needs of individual patients on the responsibility of a treating healthcare professional. How that provision is applied differs from country to country, so a process that works in one hospital may not transfer to another. Your national competent authority, or your hospital’s regulatory pharmacist, is the right place to confirm the local rule.

If you are unsure which route fits, our article on named patient programmes and compassionate use in the EU sets out the differences in plain terms.

What the treating physician needs to prepare

A supplier cannot make a clinical case for you, and it should not try. The request has to come from the prescriber, and it is quicker when it is complete from the outset. Missing information is the most common reason a first enquiry goes back and forth for weeks.

  • The exact active substance, strength and pharmaceutical form requested, plus any acceptable alternatives.
  • A written statement of clinical need and why authorised options available locally are not suitable.
  • Patient identifiers handled according to data protection rules, shared only as far as the supply route requires.
  • The quantity needed for the intended treatment period, and an expected start date.
  • Confirmation that the prescriber accepts responsibility for use of an unlicensed product, where the national rules require it.

It helps to name a single contact on the clinical side who can answer questions quickly. In rare diseases the prescriber is often one of very few specialists in the country, and supply teams need a direct line to them.

What the hospital pharmacy and procurement team need to confirm

Once the clinical request is ready, the pharmacy side takes over. The hospital pharmacist usually owns the import and authorisation steps, while procurement handles the commercial side. These two functions should speak early, before a quotation is accepted.

Check whether a prior authorisation, notification or import permit is needed from the national authority, and whether the hospital itself or the supplier must hold the relevant licence. Confirm who is the importer of record and who takes responsibility for batch documentation. Agree how the product will be received, quarantined if necessary and released to the ward or the patient.

Procurement should also ask whether the purchase falls outside existing framework contracts and whether internal approval thresholds apply. For a single patient with a time-sensitive need, an exception route inside the hospital is better agreed in advance than discovered after the order is placed. Our guide to sourcing unlicensed medicines in Europe covers the operational side in more detail.

Questions to ask a rare disease medicine supplier Europe hospitals can work with

Availability is only the opening question. A product may exist somewhere in the world and still be hard to deliver correctly to a hospital in Europe. These are the questions worth putting to any supplier, in writing, before you commit.

  1. Where does the product come from, and can the supplier show the chain of custody back to the manufacturer or marketing authorisation holder?
  2. Which licences does the supplier hold for wholesale distribution and import, and which EU Good Distribution Practice standards apply to its storage?
  3. How is temperature-sensitive product shipped, monitored and documented, and what happens if there is an excursion in transit?
  4. Which documents will accompany the delivery, such as batch certificates, certificates of analysis and product information?
  5. What are the product’s labelling and language arrangements, and how will the hospital handle a product that is not labelled in the local language?
  6. Who is the named contact for the hospital, and how are delays or changes in availability communicated?
  7. How are adverse event reports or product quality complaints passed back to the manufacturer?

A supplier that answers these clearly, and puts the answers on paper, is easier to work with than one that offers a quick price and little else. Vague answers on documentation tend to turn into problems at the pharmacy door.

Why storage and location matter

Many rare disease medicines are biologics, enzyme therapies or other products with narrow storage conditions. A supplier’s physical set-up affects how reliably such products can be held and moved. Ikris Pharma Network, for example, operates EU-GDP-certified warehouses in Belgium and Bulgaria, with offices in Bulgaria, Belgium, Hong Kong and India. For a hospital, the practical point is not the address itself but whether the supplier can show where your product will be stored and under which quality system.

Ask to see the relevant certification, and ask what happens to your product between leaving the source and arriving at your pharmacy. If a supplier uses third-party logistics, you should know which companies are involved.

Where delays usually arise

Most delays in rare disease supply are administrative rather than physical. Experienced teams learn to watch for the same few points.

  • Incomplete prescriber documentation. The authority or the supplier asks for more detail, and the request restarts.
  • Unclear responsibility for import. The hospital assumes the supplier will handle it, and the supplier assumes the opposite.
  • Late quantity changes. A change in treatment plan alters the order after paperwork has been prepared.
  • Source product not ready. The manufacturer has limited stock or release schedules that nobody checked at the beginning.
  • Customs or transport holds. Missing or mismatched documents can stop a shipment at the border.

None of these is unusual, and most can be reduced by agreeing a shared checklist at the start. A short call between the physician, pharmacist, procurement lead and supplier contact, before any order is placed, saves a good deal of correspondence later.

Planning for repeat supply

Rare disease treatment is often long-term, which means a one-off import becomes an ongoing need. Think early about how the patient will be supplied on a continuing basis. That may include scheduled re-orders, a buffer agreed with the pharmacy, and a plan for what happens if the product becomes unavailable or its status changes, for instance if it is later authorised in your country.

If your hospital is regularly handling requests of this kind, it is worth setting out a standard internal procedure and a preferred supplier route. Our named patient medicine service is designed for exactly this type of request, where a physician needs a medicine not available through the usual local channels.

Frequently Asked Questions

Can a hospital order a rare disease medicine directly from a supplier outside its own country?

Often yes, but the rules depend on the member state and on whether the product is authorised there. The hospital pharmacy should confirm import and authorisation requirements with the national authority before ordering.

Who is responsible for the clinical decision to use an unlicensed rare disease medicine?

The treating physician. A supplier provides the product and the supporting documentation, but the decision to prescribe and the responsibility for its use remain with the prescriber under national rules.

What should we look for when choosing a rare disease medicine supplier Europe-wide?

Look for clear documentation, traceable sourcing, appropriate licences, GDP-compliant storage and a named contact who responds promptly. Ask for these points in writing rather than relying on verbal assurances.

How early should we contact a supplier?

As soon as the prescriber has identified the medicine, and ideally before the formal request is complete. An early conversation helps establish availability, documents needed and a realistic timeline.

If your hospital or clinical team is working on a request for a rare disease medicine, the Ikris Pharma Network team is happy to discuss what the process involves. You can reach us through our contact page.

By Ikris Pharma Network Editorial Team

The Ikris Pharma Network editorial team writes practical guides on pharmaceutical sourcing, tenders, named patient supply and medicine access in Europe, drawing on the company’s day-to-day work with hospitals, distributors and procurement teams.

Leave a Reply

Your email address will not be published. Required fields are marked *

WhatsApp